 |
BioWorld-International-2011-05-04
Wilex Rises on Potential $145M Prometheus Deal on Rencarex
Wilex Rises on Potential $145M Prometheus Deal on Rencarex
Shares in Wilex AG rose almost 20 percent Monday on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million. (BioWorld International)
Actelion Must Pay $547M in Dispute with Asahi Kasei
LONDON – The pressure on Actelion Ltd. is intensifying after a U.S. jury said the company should pay out $547 million in its license dispute with Asahi Kasei Pharma Corp of Tokyo.
Enzyme Links Sickle Trait to Protection from Malaria
LONDON – A study has produced new clues to help explain the long-standing mystery of how people with sickle cell trait are protected against severe malaria.
Teva Outbids Valeant for Cephalon in $6.8B Cash Offer
Jerusalem-based Teva Pharmaceutical Industries Ltd. announced Monday that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.